NOT FOR DISTRIBUTION
Header cover image

Market Cap

AU$91.3m

Last Updated

2021/05/07 08:20 UTC

Data Sources

Company Financials

Executive Summary

Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases in Australia. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Actinogen Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ACW is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: ACW's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Australian stocks.


Market Performance


7 Day Return

-13.6%

ACW

0.9%

AU Biotechs

0.3%

AU Market


1 Year Return

185.0%

ACW

-8.3%

AU Biotechs

35.9%

AU Market

Return vs Industry: ACW exceeded the Australian Biotechs industry which returned -9.4% over the past year.

Return vs Market: ACW exceeded the Australian Market which returned 37.3% over the past year.


Shareholder returns

ACWIndustryMarket
7 Day-13.6%0.9%0.3%
30 Day42.5%3.6%1.8%
90 Day111.1%-1.2%2.8%
1 Year190.8%185.0%-7.4%-8.3%39.9%35.9%
3 Year35.3%32.6%62.2%56.9%30.1%14.7%
5 Year-38.1%-39.4%155.1%140.3%60.1%29.9%

Long-Term Price Volatility Vs. Market

How volatile is Actinogen Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Actinogen Medical undervalued compared to its fair value and its price relative to the market?

5.35x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ACW's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ACW's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ACW is unprofitable, so we can't compare its PE Ratio to the XX Biotechs industry average.

PE vs Market: ACW is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ACW's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ACW is overvalued based on its PB Ratio (5.3x) compared to the AU Biotechs industry average (4.8x).


Future Growth

How is Actinogen Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Actinogen Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Actinogen Medical performed over the past 5 years?

-9.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ACW is currently unprofitable.

Growing Profit Margin: ACW is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ACW is unprofitable, and losses have increased over the past 5 years at a rate of 9.4% per year.

Accelerating Growth: Unable to compare ACW's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: ACW has a negative Return on Equity (-23.59%), as it is currently unprofitable.


Financial Health

How is Actinogen Medical's financial position?


Financial Position Analysis

Short Term Liabilities: ACW's short term assets (A$13.0M) exceed its short term liabilities (A$847.2K).

Long Term Liabilities: ACW's short term assets (A$13.0M) exceed its long term liabilities (A$257.2K).


Debt to Equity History and Analysis

Debt Level: ACW is debt free.

Reducing Debt: ACW has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACW has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ACW has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 11.9% each year


Dividend

What is Actinogen Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACW's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACW's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACW's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ACW's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average management tenure


CEO

Steve Gourlay (60 yo)

0.17

Tenure

Dr. Steven G. Gourlay, also known as Steve, MBBS (M.D.), Ph.D., FRACP, M.B.A., serves as Chief Executive Officer at Actinogen Medical Limited since March 15, 2021 and as its Managing Director and Director ...


Leadership Team

Experienced Management: ACW's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: ACW's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ACW insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.8%.


Top Shareholders

Company Information

Actinogen Medical Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Actinogen Medical Limited
  • Ticker: ACW
  • Exchange: ASX
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$91.331m
  • Shares outstanding: 1.66b
  • Website: https://www.actinogen.com.au

Location

  • Actinogen Medical Limited
  • 109 Pitt Street
  • Suite 901
  • Sydney
  • New South Wales
  • 2000
  • Australia

Listings


Biography

Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases in Australia. The company is develo...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/07 08:20
End of Day Share Price2021/05/07 00:00
Earnings2020/12/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.